Structural Endpoints and Outcome Measures in Uveitis
Ophthalmologica · 2021 · 244 (5) · 465-479
DOI: 10.1159/000517521 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Ophthalmologica, online erschienen am 01.06.2021. Verfasst von Maximilian W M Wintergerst und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, University Hospital Bonn, Bonn, Germany, maximilian.wintergerst@ukbonn.de. Hauptthemen laut MEDLINE: Uveitis. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 173 Literaturangaben. Gefördert von: Wellcome Trust, Medical Research Council.
Abstract (Originalsprache)
Most uveitis entities are rare diseases but, taken together, are responsible for 5–10% of worldwide visual impairment which largely affects persons of working age. As with many rare diseases, there is a lack of high-level evidence regarding its clinical management, partly due to a dearth of reliable and objective quantitative endpoints for clinical trials. This review provides an overview of available structural outcome measures for uveitis disease activity and damage in an anatomical order from the anterior to the posterior segment of the eye. While there is a multitude of available structural outcome measures, not all might qualify as endpoints for clinical uveitis trials, and thorough testing of applicability is warranted. Furthermore, a consensus on endpoint definition, standardization, and “core outcomes” is required. As stipulated by regulatory agencies, endpoints should be precisely defined, clinically important, internally consistent, reliable, responsive to treatment, and relevant for the respective subtype of uveitis. Out of all modalities used for assessment of the reviewed structural outcome measures, optical coherence tomography, color fundus photography, fundus autofluorescence, and fluorescein/indocyanine green angiography represent current “core modalities” for reliable and objective quantification of uveitis outcome measures, based on their practical availability and the evidence provided so far.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Ophthalmology, University Hospital Bonn, Bonn, Germany, maximilian.wintergerst@ukbonn.de.
- Department of Ophthalmology, Queen Elizabeth Hospital Birmingham, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom.
- Academic Unit of Ophthalmology, Institute of Inflammation & Ageing, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom.
- Health Data Research UK, London, United Kingdom.
- Department of Ophthalmology, University Hospital Bonn, Bonn, Germany.
- Berlin Institute of Health, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin, Germany.
Förderung
- Wellcome Trust
- Medical Research Council
Zitieren
APA
Wintergerst, M. W. M., Liu, X., Terheyden, J. H., Pohlmann, D., Li, J. Q., Montesano, G., Ometto, G., Holz, F. G., Crabb, D. P., Pleyer, U., Heinz, C., Denniston, A. K., & Finger, R. P. (2021). Structural Endpoints and Outcome Measures in Uveitis. Ophthalmologica, 244(5), 465-479. https://doi.org/10.1159/000517521
Vancouver
Wintergerst MWM, Liu X, Terheyden JH, Pohlmann D, Li JQ, Montesano G, et al. Structural Endpoints and Outcome Measures in Uveitis. Ophthalmologica. 2021;244(5):465-479. doi:10.1159/000517521
BibTeX
@article{Wintergerst2021,
author = {Wintergerst, Maximilian W M and Liu, Xiaoxuan and Terheyden, Jan H and Pohlmann, Dominika and Li, Jeany Q and Montesano, Giovanni and Ometto, Giovanni and Holz, Frank G and Crabb, David P and Pleyer, Uwe and Heinz, Carsten and Denniston, Alastair K and Finger, Robert P},
title = {Structural Endpoints and Outcome Measures in Uveitis},
journal = {Ophthalmologica},
year = {2021},
volume = {244},
number = {5},
pages = {465--479},
doi = {10.1159/000517521}
}
EUVIMED